To ensure patients fully benefit from this era of rapid medical innovation, a new USC Schaeffer Center white paper outlines significant #FDA reforms to:
🔹streamline clinical trials
🔹provide certainty to innovators
🔹improve access to new treatments
https://t.co/F04DlhpAeB
📅 Join us Sept. 19 for a conference on #FDA policy reforms aimed at reducing drug development costs and getting valuable new treatments to patients faster.
Speakers include: @ScottGottliebMD, Janet Woodcock, @KDrazan & @LowellSchiller
➡️Registration: https://t.co/c1mzp4bxLh
Conflicts of interest for HHS vaccine panels hit record lows before RFK Jr took over as the top health secretary. Kennedy has repeatedly said he wants to "clean out" corruption and fired the CDC's panel over supposed conflicts. @business
https://t.co/C4iyz0dL9v
The total economic burden of #Alzheimers and related dementias in the US will hit $781B this year, finds research led by the @USC Schaeffer Center.
The researchers aim to provide the most comprehensive accounting yet of dementia’s growing economic toll.
https://t.co/8oiZFrRD9k
Medicare's decision not to broadly cover highly effective anti-obesity medications was a missed opportunity to make America healthier and richer, USC Schaeffer's Alison Sexton Ward and Dana Goldman write in the @washingtonpost. https://t.co/aenty4oL03
With #Medicare open-enrollment closing on Saturday, a recent #USCSchaeffer study underscores the health and financial risks of failing to shop around for prescription drug plans.
https://t.co/wO43cvVLxO
A long-awaited CBO report projects #Medicare coverage of anti-obesity medications will increase federal spending through 2034.
But a review of CBO's calculation finds clues that the report may not be the final word on how Congress will view these drugs. https://t.co/715Vd9cbej
Medicare Advantage is being overpaid by more than $80B this year, write Paul Ginsburg and Steve Lieberman of #USCSchaeffer.
If left alone, MA "will increasingly push overall costs in Medicare into unsustainable territory." Needed reforms can be phased in over years, they say.
A small number of PBMs dominated the Medicare Part D, Medicaid and commercial markets in 2023, and the 3 biggest PBMs may each be targeting different payer markets, according to new #USCSchaeffer research in @JAMA_current. https://t.co/1FbXl1QK29
The vast majority of people who don't question a troubling medical bill think it's not worth the effort. But new @SchaefferCenter research in @JAMAHealthForum finds that most who contact a billing office for help get some form of financial relief. https://t.co/9XpKngtOi3
📆 Join us in DC on Sept. 25 for a conversation on the future of Medicare's Coverage with Evidence Development policy. We're co-hosting the event at USC's Capital Campus with @TuftsCEVR and @SUBiodesign.
Register here to join in-person or virtually: https://t.co/Xei9xB3sPN
A study led by #USCPrice professor Wändi Bruine de Bruin shows that people are more familiar with and concerned about the terms "climate change" and "global warming" compared to their over-heated alternatives.
Read more here:
https://t.co/ZkMckTf6CP
@USCDornsife@USCWrigley
Ozempic and Wegovy prescription fills soared over 400% in just two years, but private insurance patients are far more likely to receive them than #Medicare and #Medicaid patients, found #USCSchaeffer Center research published in @JAMAHealthForum.
https://t.co/wyomgWaVGm
New: As policymakers weigh #PBM measures, USC @SchaefferCenter experts outline 5 patient-focused principles for reform. Recommendations are informed by the Center's nearly decade of research into the complex & opaque drug supply chain. https://t.co/Gwy8kwjhYb
The new Behavioral Science & Policy Initiative at the @USC Schaeffer Institute will study people's beliefs and behaviors to create better policies and communication, with a focus on climate change, health and food insecurity.
https://t.co/ItBwxAHUAJ